Spectra Optia® IDL-Set
DevicePeripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
NCT Number: NCT01901458
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system. The study will assess the reduction of apheresis time to obtain the required amount of hematopoietic progenitor cells.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Cellex GmbH / Zentrum für Zellgewinnung (Standort Köln), Cologne, Germany
Peripheral blood progenitor cells (PBPC) collected by apheresis are the most common stem cell source for allogeneic hematopoietic stem cell transplantation.
Recently, Terumo BCT introduced a novel automated apheresis system for PBPC collection. The Spectra Optia® apheresis system uses the Spectra Optia® Collection set and the MNC software for PBPC collection. This system combines continuous centrifugation (high g) and subsequent cellular collection into an elutriation chamber, where the platelets are elutriated from mononuclear cells. An optical sensor detects when red blood cells begin to be elutriated and subsequently triggers the collection of the buffy coat into the product bag by flushing the chamber with donor plasma. Thus PBPCs are harvested intermittently. In contrast, the same apheresis systems in combination with the Spectra Optia® IDL set and the WBC-D software, which has been designed to perform leukodepletion procedures, permits continuous PBPC centrifugation (low g) and harvesting.
The investigators hypothesis is that the use of the IDL set with manual adaption of the WBC-D-software allows a more efficient PBPC collection compared to the collection set which is recommended for PBPC collection. The apheresis time to collect the same amount of target cells dependent on the donors peripheral blood count will be shortened. In addition, the investigators want to compare both systems with respect to the cellular composition of the apheresis product and the donors platelet loss and coagulation parameters during apheresis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
Time frame: Day 1
Efficiency of peripheral blood progenitor cell collection measured as throughput (collection rate (CR) per minute)
Time frame: Day 1
Efficiency of peripheral blood progenitor cell collection measured as CR per TBV
Time frame: Day 1
Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell counts pre and post apheresis)
Time frame: Day 1
Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell count pre apheresis)
Time frame: Day 1
% T cells as a definition of the cellular composition of the product
Time frame: Day 1
% NK cells as a definition of the cellular composition of the product
Time frame: day 1, day 30
sodium, potassium and calcium are measured before and after apherese and 30 days after collection
Time frame: day 1, day30
measurement of the peripheral blood cell count before and after apheresis and 30 days after collection
Time frame: day 1
Percentage of CD62P positive platelets as a measure of platelet activation during apheresis
Heinrich-Heine University, Duesseldorf
Other
Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set
Acronym: optiMaL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.